This excerpt taken from the BMRN 10-K filed Mar 7, 2006.
We have developed Vibrilase through Phase 1b as a topically applied enzyme for the debridement of serious burns. In August 2004, we announced positive data from our European Phase 1b clinical trial. Data from the study suggest that treatment with Vibrilase is generally safe and well tolerated. Although the trial was designed to measure safety and tolerability, the preliminary efficacy data suggest that Vibrilase is effective in debriding partial-thickness burns. We are currently evaluating options for this program and are in the process of applying for an Orphan Drug designation.
This excerpt taken from the BMRN 10-K filed Mar 16, 2005.
Other enzymatic products exist besides Vibrilase that may be used for the debridement of serious second or third degree burns. Those products in their current form have not captured any meaningful share of the debridement function in the treatment of burn patients. However, we are aware of another company that is developing an enzymatic product for the debridement of serious burns. The primary competition for Vibrilase continues to be surgical debridement.